Trial reportScientific reports2026
Effectiveness of voluntary isocapnic hyperpnoea for mitigating hypoxemia and acute mountain sickness in normobaric hypoxia: a randomized crossover pilot trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to examine the physiological mechanisms associated with Voluntary Isocapnic Hyperpnoea (VIH) in severe hypoxia and evaluated whether such respiratory modulation may attenuate hypoxemia and Acute Mountain Sickness (AMS). Eighteen healthy participants (8 females) completed two 2-hour sessions in a normobaric hypoxic chamber simulating 4200 m above sea level, in randomized order: an experimental session including a 5-minute VIH intervention after 1 h, and a control session without VIH. AMS symptoms, arterial oxygen saturation (SpO₂), heart rate, blood pressure and gases were monitored before and during the hypoxic exposure. Separate repeated-measures ANOVAs were employed to analyze the effects of VIH and differences between the sessions. VIH decreased clinical hypoxemia (from 83.3% to 22.2%) and reduced AMS incidence (from 11.1% to 5.5%). This was associated with an increase in SpO₂ (p = 0.011, ηp
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.